Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Pharmacometrics and systems pharmacology for metabolic bone diseases.

Riggs MM, Cremers S.

Br J Clin Pharmacol. 2019 Jun;85(6):1136-1146. doi: 10.1111/bcp.13881. Epub 2019 Feb 28. Review.

PMID:
30690761
2.

When Learn/Confirm Leads to Expand/Understand: The Expanding Role of Quantitative Systems Pharmacology in the Betterment of Therapeutics Development.

Riggs MM.

Clin Pharmacol Ther. 2019 Mar;105(3):558-560. doi: 10.1002/cpt.1287. Epub 2018 Dec 18. No abstract available.

PMID:
30565207
3.

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis.

Eudy-Byrne RJ, Gillespie W, Riggs MM, Gastonguay MR.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):599-609. doi: 10.1007/s10928-017-9551-z. Epub 2017 Oct 28.

PMID:
29081020
4.

Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics.

Ocampo-Pelland AS, Gastonguay MR, Riggs MM.

J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):375-388. doi: 10.1007/s10928-017-9525-1. Epub 2017 May 2.

PMID:
28466367
5.

Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data.

Ocampo-Pelland AS, Gastonguay MR, French JF, Riggs MM.

J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):191-206. doi: 10.1007/s10928-016-9465-1. Epub 2016 Feb 12.

PMID:
26872884
6.

Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model.

Eudy RJ, Gastonguay MR, Baron KT, Riggs MM.

CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):527-36. doi: 10.1002/psp4.12013. Epub 2015 Sep 11.

7.

FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?

Peterson MC, Riggs MM.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00020. doi: 10.1002/psp4.20. Epub 2015 Mar 12.

8.

A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.

Eudy RJ, Riggs MM, Gastonguay MR.

AAPS J. 2015 Sep;17(5):1280-4. doi: 10.1208/s12248-015-9795-8. Epub 2015 Jun 16.

9.

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Riggs MM, Seman LJ, Staab A, MacGregor TR, Gillespie W, Gastonguay MR, Woerle HJ, Macha S.

Br J Clin Pharmacol. 2014 Dec;78(6):1407-18. doi: 10.1111/bcp.12453.

10.

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.

Riggs MM, Staab A, Seman L, MacGregor TR, Bergsma TT, Gastonguay MR, Macha S.

J Clin Pharmacol. 2013 Oct;53(10):1028-38. doi: 10.1002/jcph.147. Epub 2013 Aug 13.

PMID:
23940010
11.

Facilitating pharmacometric workflow with the metrumrg package for R.

Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR.

Comput Methods Programs Biomed. 2013 Jan;109(1):77-85. doi: 10.1016/j.cmpb.2012.08.009. Epub 2012 Sep 29.

PMID:
23026560
12.

Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function.

Riggs MM, Peterson MC, Gastonguay MR.

J Clin Pharmacol. 2012 Jan;52(1 Suppl):45S-53S. doi: 10.1177/0091270011412967.

PMID:
22232752
13.

Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.

Riggs MM, Bennetts M, van der Graaf PH, Martin SW.

CPT Pharmacometrics Syst Pharmacol. 2012 Oct 17;1:e11. doi: 10.1038/psp.2012.10.

14.

Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.

Peterson MC, Riggs MM.

CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1:e14. doi: 10.1038/psp.2012.15.

15.

Population pharmacokinetics and exposure-response of albinterferon alfa-2b.

Riggs MM, Bergsma TT, Rogers JA, Gastonguay MR, Subramanian GM, Chen C, Devalaraja M, Corey AE, Sun H, Yu J, Stein DS.

J Clin Pharmacol. 2012 Apr;52(4):475-86. doi: 10.1177/0091270011399576. Epub 2011 May 6.

PMID:
21551316
16.

Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.

Jump RL, Riggs MM, Sethi AK, Pultz MJ, Ellis-Reid T, Riebel W, Gerding DN, Salata RA, Donskey CJ.

Emerg Infect Dis. 2010 May;16(5):827-9. doi: 10.3201/eid1605.071606.

17.

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling.

Peterson MC, Riggs MM.

Bone. 2010 Jan;46(1):49-63. doi: 10.1016/j.bone.2009.08.053. Epub 2009 Sep 2.

PMID:
19732857
18.

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ.

Antimicrob Agents Chemother. 2008 Jul;52(7):2403-6. doi: 10.1128/AAC.00090-08. Epub 2008 Apr 28.

19.

Recurrent infection with epidemic Clostridium difficile in a peripartum woman whose infant was asymptomatically colonized with the same strain.

Hecker MT, Riggs MM, Hoyen CK, Lancioni C, Donskey CJ.

Clin Infect Dis. 2008 Mar 15;46(6):956-7. doi: 10.1086/527568. No abstract available.

PMID:
18288909
20.

Clostridium difficile skin contamination in patients with C. difficile-associated disease.

Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ.

Clin Infect Dis. 2008 Feb 1;46(3):447-50. doi: 10.1086/525267.

PMID:
18181742
21.

Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.

Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ.

Clin Infect Dis. 2007 Oct 15;45(8):992-8. Epub 2007 Sep 4.

PMID:
17879913
22.
23.

Population pharmacokinetics/pharmacodynamics and individualized drug therapy.

Riggs MM.

J Am Pharm Assoc (Wash). 1997 Jan-Feb;NS37(1):59-61; discussion 58.

PMID:
9040170
24.

An attempt to influence the Rorschach test by means of a peripheral set.

KURTZ JC, RIGGS MM.

J Consult Psychol. 1954 Dec;18(6):465-70. No abstract available.

PMID:
13221718
25.

Comparison of three etiological groups of mentally retarded children on the Vineland social maturity scale.

CASSEL ME, RIGGS MM.

Am J Ment Defic. 1953 Jul;58(1):162-9. No abstract available.

PMID:
13057922
26.
27.

Supplemental Content

Loading ...
Support Center